Buying Dynal, Invitrogen Would Get a Foothold in an FDA-Regulated Market | GenomeWeb

Invitrogen said Tuesday it will spend approximately $386 million to purchase privately held Dynal Biotech of Oslo, Norway.

The proposed acquisition, which includes Dynal’s Dynabeads magnetic separation-technology business as well as its HLA diagnostics segment, would move Invitrogen for the first time into an FDA-regulated market and potentially give it access to Dynal’s in vitro diagnostics customers like Roche Diagnostics and Bayer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.